HER2-Positive Breast Cancer is a type of breast cancer that is caused by an over-expression of a gene called the HER2 gene. This gene is responsible for producing a protein called HER2/neu, which is found on the surface of some types of breast cancer cells. When the HER2/neu protein is over-expressed, it causes the abnormal growth of these cells, leading to an aggressive form of breast cancer.
Download Free Sample of Report – https://www.globalinsightservices.com/request-sample/GIS26121
HER2-Positive Breast Cancer is more aggressive than other types of breast cancer and is more likely to spread to other parts of the body. It is also more likely to recur after treatment and is associated with a poorer prognosis. The HER2 gene is found in about one in five breast cancers, making it one of the most common types of breast cancer.
Treatment for HER2-Positive Breast Cancer typically involves a combination of chemotherapy, targeted therapy, hormonal therapy, and/or surgery. Targeted therapy is a type of treatment that targets the HER2 gene specifically, and can help stop the growth of the cancer cells. Hormonal therapy is used to block the effects of hormones on the cancer cells, and surgery may be used to remove the cancerous cells and any affected lymph nodes.
HER2-Positive Breast Cancer can be a frightening diagnosis, but with the right treatment and support, it can be managed. It is important to seek the advice of an experienced team of doctors to find the best treatment plan for you.
Key Trends
The field of HER2-positive breast cancer technology is rapidly evolving, with new developments and treatments being developed every year. HER2-positive breast cancer is a particularly aggressive form of breast cancer, and the development of new technologies is critical for improving patient outcomes.
One of the main trends in HER2-positive breast cancer technology is the development of targeted therapies. These therapies are designed to target the specific mutations or abnormalities that drive HER2-positive cancer growth. Examples of targeted therapies include monoclonal antibodies, such as trastuzumab (Herceptin) and pertuzumab (Perjeta), which are designed to bind to the HER2 receptor and block its action. There are also other targeted therapies, such as tyrosine kinase inhibitors (TKIs), which inhibit the activity of the HER2 receptor. These targeted therapies are becoming increasingly popular, as they are more effective than traditional chemotherapy and can reduce the side effects associated with chemotherapy.
Report Overview– https://www.globalinsightservices.com/reports/her2-positive-breast-cancer-market/
Another key trend in HER2-positive breast cancer technology is the development of novel combination therapies. Combination therapies involve the use of multiple drugs in combination to target different aspects of the cancer. These combination therapies are becoming increasingly popular, as they can provide more effective treatment than single drugs alone. For example, Herceptin and Perjeta are often used in combination with chemotherapy and/or other targeted therapies, such as TKIs, to provide a more effective treatment.
In addition, there is a growing trend towards personalized medicine for HER2-positive breast cancer. This involves the use of genetic testing to identify the best treatment for a particular patient. For example, the Oncotype DX test can help predict which patients will respond best to chemotherapy, and which patients will benefit from targeted therapies. This personalized approach is becoming increasingly important, as it can help ensure that patients receive the most effective treatment for their specific cancer.
Finally, there is a trend towards the development of new imaging technologies for HER2-positive breast cancer. This includes the development of PET scans, which can provide detailed images of the tumor and help identify the best treatment option. Additionally, MRI scans are becoming increasingly important for detecting and monitoring the progression of HER2-positive breast cancer.
Overall, the field of HER2-positive breast cancer technology is rapidly evolving, with new treatments and technologies being developed every year. The development of targeted therapies, combination therapies, personalized medicine, and imaging technologies are all key trends that are helping to improve patient outcomes.
Key Drivers
The key drivers of the HER2-positive breast cancer market are the increasing prevalence of the disease, rising awareness of the disease, and advancements in treatment.
HER2-positive breast cancer is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2) on the surface of the cancer cells. This type of breast cancer tends to be more aggressive and is associated with poorer prognosis than other types. It is estimated that approximately 15-20 % of all breast cancers are HER2 positive.
The prevalence of HER2-positive breast cancer is increasing due to an aging population and the growing awareness of the disease. The increased awareness of the disease has led to more women seeking screening and early detection, leading to a higher incidence of the disease. Additionally, there has been an increase in the number of women who are delaying childbearing, which is a known risk factor for breast cancer.
Get a customized scope to match your need, ask an expert – https://www.globalinsightservices.com/request-customization/GIS26121
Advances in treatment have also been a key driver of the HER2-positive breast cancer market. New therapies such as targeted therapies, immunotherapies, and combination therapies have improved outcomes for patients with this type of breast cancer. In particular, targeted therapies such as trastuzumab, pertuzumab, and lapatinib have been shown to be effective in treating HER2-positive breast cancer. In addition, immunotherapies such as pembrolizumab and atezolizumab have been approved for the treatment of HER2-positive breast cancer. The approval of these therapies has been a major driver of the HER2-positive breast cancer market.
Furthermore, the increasing focus on personalized medicine has also been a key driver of the HER2-positive breast cancer market. Personalized medicine involves tailoring treatments to the individual patient’s needs and is becoming increasingly important in the treatment of HER2-positive breast cancer. The use of biomarkers such as HER2, hormone receptors, and other markers, to identify the best treatment options for the individual patient is becoming more common.
In conclusion, the key drivers of the HER2-positive breast cancer market are the increasing prevalence of the disease, rising awareness of the disease, and advancements in treatment. These drivers have led to an increase in the number of women seeking screening and early detection, leading to a higher incidence of the disease, and the approval of new therapies which have improved outcomes for patients. Additionally, the increasing focus on personalized medicine has also been a key driver of the HER2-positive breast cancer market.
Market Segmentation
The market can be segmented by treatment type, route of administration, end-users, and region. By Treatment Type, the market can be divided into Chemotherapy, Targeted Therapy, Immunotherapy, and Others. By Route of Administration, the market can be divided into Oral, Parenteral, and Others. By End-Users, the market can be divided into Hospitals, Homecare, Speciality Centres, and Others. By Region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.
Key Players
The market includes players such as Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India, Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), and Pfizer Inc (U.S.).
Buy Now – https://www.globalinsightservices.com/checkout/single_user/GIS26121
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/